Bodenstedt Matthias 4

What Happened
Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 17,876 shares in open-market transactions on June 17–18, 2026, receiving aggregate proceeds of about $351,576. The larger sale on June 17 was 15,082 shares at a weighted average price of $19.68 ($296,814), and the June 18 sale was 2,794 shares at a weighted average price of $19.60 ($54,762). These were sales (not purchases).

Key Details

• Dates and prices:
  • 2026-06-17: 15,082 shares sold, weighted average price $19.68; reported price range $19.50–$20.06 (F2).
  • 2026-06-18: 2,794 shares sold, weighted average price $19.60; reported price range $19.505–$19.70 (F3).
• Total shares sold: 17,876; total proceeds ≈ $351,576.
• Footnotes:
  • F1: Transactions executed under a Rule 10b5-1 trading plan adopted December 10, 2025 (pre‑arranged plan).
  • F2/F3: Reported prices are weighted averages; the filer notes the SEC, the issuer, or a security holder can request a breakdown of shares sold at each separate price.
• Shares owned after transaction: Not specified in the summary information provided on this Form 4.
• Timeliness: Form filed June 18, 2026 for transactions on June 17–18, 2026 (filed within the typical Form 4 reporting window).

Context
The sales were executed under a pre-established 10b5-1 trading plan, which is commonly used to schedule trades in advance and can reduce the appearance that trades are based on nonpublic information. The filing shows routine insider sales; it does not provide evidence of the insider’s motivations.